Supernus Pharmaceuticals Logo

Supernus Pharmaceuticals

🇺🇸
SUPN
US8684591089

Supernus Pharmaceuticals develops and commercializes innovative therapies for central nervous system disorders. The company focuses on neurology and psychiatry to offer high-quality treatment options for patients with complex CNS conditions. Its core activities include research, development, and marketing of new medications aimed at improving quality of life.

Next Quarterly Earnings

Tuesday, August 11, 2026
CW 33
After-Hours
In 37 days

Stock Price

All Dates

Company Information

Name
Supernus Pharmaceuticals
Ticker Symbol
SUPN
ISIN
US8684591089
Country
🇺🇸
USA